Business Description
DiaMedica Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA25253X1087
Description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 137.53 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 8.4 | |||||
| 3-Year FCF Growth Rate | 0.7 | |||||
| 3-Year Book Growth Rate | -1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -13.76 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 90.68 | |||||
| 9-Day RSI | 83.07 | |||||
| 14-Day RSI | 77.03 | |||||
| 6-1 Month Momentum % | 56.52 | |||||
| 12-1 Month Momentum % | 72.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.81 | |||||
| Quick Ratio | 11.81 | |||||
| Cash Ratio | 11.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.5 | |||||
| Shareholder Yield % | 0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -42.66 | |||||
| ROA % | -40.06 | |||||
| ROIC % | -624.08 | |||||
| ROC (Joel Greenblatt) % | -5069.39 | |||||
| ROCE % | -47.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.04 | |||||
| Price-to-Tangible-Book | 5.05 | |||||
| EV-to-EBIT | -7.96 | |||||
| EV-to-EBITDA | -7.97 | |||||
| EV-to-FCF | -9.86 | |||||
| Price-to-Net-Current-Asset-Value | 5.24 | |||||
| Price-to-Net-Cash | 5.29 | |||||
| Earnings Yield (Greenblatt) % | -12.56 | |||||
| FCF Yield % | -8.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DMAC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DiaMedica Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.56 | ||
| Beta | 0.89 | ||
| Volatility % | 38.78 | ||
| 14-Day RSI | 77.03 | ||
| 14-Day ATR ($) | 0.279817 | ||
| 20-Day SMA ($) | 4.422 | ||
| 12-1 Month Momentum % | 72.8 | ||
| 52-Week Range ($) | 2.14 - 5.66 | ||
| Shares Outstanding (Mil) | 42.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DiaMedica Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DiaMedica Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
DiaMedica Therapeutics Inc Frequently Asked Questions
What is DiaMedica Therapeutics Inc(DMAC)'s stock price today?
The current price of DMAC is $5.66. The 52 week high of DMAC is $5.66 and 52 week low is $2.14.
When is next earnings date of DiaMedica Therapeutics Inc(DMAC)?
The next earnings date of DiaMedica Therapeutics Inc(DMAC) is 2025-03-20 Est..
Does DiaMedica Therapeutics Inc(DMAC) pay dividends? If so, how much?
DiaMedica Therapeutics Inc(DMAC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers